NASDAQ$KALV
KalVista Pharmaceuticals Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
KalVista reported third fiscal quarter results with enrollment in sebetralstat KONFIDENT phase 3 trial passing 50% milestone and funding secured into 2025.
KalVista Pharmaceuticals announced its third fiscal quarter results, highlighting significant progress in its sebetralstat development program, including the KONFIDENT phase 3 trial and new funding that extends operations into 2025. The company reported a net loss of $21.3 million, but also announced $58 million in new funding.
- Sebetralstat KONFIDENT phase 3 trial enrollment passed the 50% milestone, with data expected in H2 2023.
- Sebetralstat phase 2 data was published in The Lancet.
- The company secured funding into 2025 through a registered direct offering.
- New data on sebetralstat was presented at the 2023 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.
Headline financials
Revenue & EPS history
KalVista · Revenue · Quarterly
$13.7M
Forward guidance
KalVista intends to use the proceeds of the $58 million offering to fund clinical trials, commercial sales development, research, working capital, capital expenditures and other general corporate purposes. The company expects to be able to fund operations into 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
-0.3%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-0.7%
Avg return
30 days after
49%
21 / 43 earnings
Positive
+20.3%
Q4 2018
Best reaction
-26.3%
Q3 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | +1.1% | +26.3% | +56.4% | |
| Q1 2026 | -3.8% | -12.3% | -25.3% | |
| Q4 2025 | -3.1% | -5.1% | -22.4% | |
| Q3 2025 | +2.0% | -2.6% | +5.1% | |
| Q2 2025 | -4.2% | -0.2% | -4.5% | |
| Q1 2025 | -4.5% | -13.2% | -12.1% | |
| Q4 2024 | +3.7% | +21.3% | +2.6% | |
| Q3 2024 | -13.0% | -16.9% | -16.9% | |
| Q2 2024 | -9.0% | +8.8% | +26.8% | |
| Q1 2024 | -4.0% | -4.2% | -12.2% | |
| Q4 2023 | +17.0% | +7.6% | +23.5% | |
| Q3 2023 | -10.4% | -1.3% | +2.7% | |
| Q2 2023 | +9.8% | +7.3% | +27.8% | |
| Q1 2023 | +1.4% | -2.5% | -68.4% | |
| Q4 2022 | +10.6% | +18.0% | +37.5% | |
| Q3 2022 | -9.3% | -14.6% | -16.4% | |
| Q2 2022 | -0.4% | -2.9% | -4.2% | |
| Q1 2022 | -0.6% | -6.0% | -14.4% | |
| Q4 2021 | -3.0% | -2.9% | -14.0% | |
| Q3 2021 | +3.4% | +8.9% | -16.8% | |
| Q2 2021 | +5.2% | +5.1% | -7.0% | |
| Q1 2021 | +2.0% | +1.3% | +9.8% | |
| Q4 2020 | +7.2% | +4.2% | -18.8% | |
| Q3 2020 | -26.3% | -41.2% | -20.9% | |
| Q2 2020 | -1.8% | -5.7% | +18.9% | |
| Q1 2020 | +8.7% | +1.0% | -29.4% | |
| Q4 2019 | -0.5% | +1.4% | -6.7% | |
| Q3 2019 | +10.4% | +7.6% | -0.2% | |
| Q2 2019 | -14.0% | -21.2% | -15.5% | |
| Q1 2019 | +9.6% | +4.6% | +20.6% | |
| Q4 2018 | +20.3% | +29.8% | +94.0% | |
| Q3 2018 | +4.7% | +11.7% | +0.8% | |
| Q2 2018 | -4.8% | -12.3% | +0.2% | |
| Q1 2018 | -21.5% | -23.6% | +9.8% | |
| Q4 2017 | -0.8% | -2.7% | -11.6% | |
| Q3 2017 | +1.9% | -1.0% | -12.2% | |
| Q2 2017 | -1.9% | -2.9% | -1.6% | |
| Q1 2017 | +0.4% | +13.1% | -13.3% | |
| Q4 2016 | -3.2% | — | — | |
| Q3 2016 | +7.1% | — | — | |
| Q2 2016 | -3.2% | — | — | |
| Q1 2016 | +1.3% | — | — | |
| Q4 2015 | +2.4% | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro